Loading clinical trials...

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer | Clinical Trials | Clareo Health

RECRUITINGNA

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

NCT06423963•H. Lee Moffitt Cancer Center and Research Institute

Summary

The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18 years or older
•Biopsy-proven pancreatic ductal adenocarcinoma (PDAC), borderline resectable at diagnosis
•Eastern Cooperative Oncology Group (ECOG) performance status 0-2
•Undergoing neoadjuvant chemotherapy with treatment plan including chemoradiation therapy and surgical resection
•Ability to read and speak English

Exclusion Criteria

•Regular engagement in RT (2x/week targeting all major muscle groups)
•Screen failure for exercise safety based on PAR-Q
•Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
•Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT
•Numeric pain rating scale greater than or equal to a 7 out of 10
•Myopathic or rheumatologic disease that impacts physical function

Locations (1)

Moffitt Cancer Center

Tampa, Florida, United States

Key Dates

Start Date

February 9, 2024

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

February 9, 2026

Enrollment

ESTIMATED participants

Conditions

Pancreatic Cancer

Interventions

Physical Activity

BEHAVIORAL

Nutrition Counseling

BEHAVIORAL

Resistance Training

BEHAVIORAL

Contacts

Morgan Bean

CONTACT

813-745-1786 morgan.bean@moffitt.org

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients